Synapses are asymmetric cellular adhesions that are critical for nervous system development and function, but the mechanisms that induce their formation are not well understood. We have previously identified thrombospondin as an astrocyte-secreted protein that promotes central nervous system (CNS) synaptogenesis. Here, we identify the neuronal thrombospondin receptor involved in CNS synapse formation as a2d-1, the receptor for the anti-epileptic and analgesic drug gabapentin. We show that the VWF-A domain of a2d-1 interacts with the epidermal growth factor-like repeats common to all thrombospondins. a2d-1 overexpression increases synaptogenesis in vitro and in vivo and is required postsynaptically for thrombospondin-and astrocyte-induced synapse formation in vitro. Gabapentin antagonizes thrombospondin binding to a2d-1 and powerfully inhibits excitatory synapse formation in vitro and in vivo. These findings identify a2d-1 as a receptor involved in excitatory synapse formation and suggest that gabapentin may function therapeutically by blocking new synapse formation.
INTRODUCTION
Central nervous system (CNS) synapses are complex cell-cell adhesions between neurons. Their establishment requires an interaction between axons and dendrites, accompanied by the appositional organization of pre-and postsynaptic specializations. Several neuronal cell surface molecules and secreted signals have been shown to be involved in processes that lead to synaptic organization and maturation (Fox and Umemori, 2006) , but molecules that regulate the formation of initial synaptic adhesions remain poorly understood. Accumulating evidence from our lab and others has shown that astrocytes play active roles in the formation of synapses . We have previously identified thrombospondins (TSP) as a necessary and sufficient synaptogenic signal secreted by astrocytes that increases synapse number (Christopherson et al., 2005) . TSP is present in astrocyte-conditioned media (ACM) and is responsible for the ability of astrocytes to increase synapse number in vitro (Christopherson et al., 2005) . TSPs are also important for synapse formation in vivo. TSP1/2-deficient mice have a significant decrease in the number of excitatory synapses. TSP1 and 2 are expressed during early postnatal ages, when the majority of synapses are forming, and these proteins are absent from the adult brain when the amount of excitatory synaptogenesis is significantly reduced (Christopherson et al., 2005) . Upon injury to the CNS, TSP1/2 levels are upregulated, and lack of TSP1/2 impairs synaptic and functional recovery from stroke (Liauw et al., 2008) .
TSP is able to promote synaptic adhesion and initiate the events that lead to the establishment of pre-and postsynaptic specializations. Interestingly, these TSP-induced synapses are ultrastructurally identical to fully developed synapses and are presynaptically active but postsynaptically silent because of the lack of surface AMPA receptors. Astrocytes secrete a second unrelated signal that is able to convert these silent synapses into fully active ones (Christopherson et al., 2005) (N.J.A. and B.A.B. unpublished 
data).
TSPs are large oligomeric, multidomain, extracellular matrix proteins that have been previously shown to play important roles in cell attachment, cell migration, cytoskeletal dynamics, and angiogenesis (Bornstein et al., 2004) . TSP mediates these functions via its interaction with various cell surface receptors through specific domains (Adams and Lawler, 2004) . We hypothesized that TSPs induce synapse formation by interacting with a neuronal cell-surface receptor. Here, we show that TSPs mediate synaptogenesis through their epidermal growth factor (EGF)-like domains, common to all TSP isoforms. Using this domain information, we identified the gabapentin receptor a2d-1 as the TSP receptor involved in synapse formation.
a2d-1 (Cacna2d1) was originally isolated as a nonessential subunit of the L-type calcium channel complex from skeletal muscle (Arikkath and Campbell, 2003) , and it also binds to other proteins (Kaltenbach et al., 2007) . a2d-1 is ubiquitously expressed in many tissues and is highly expressed by many CNS neurons (Cole et al., 2005) , including retinal ganglion cells (RGCs). a2d-1 is translated from a single gene product, which gets posttranslationally cleaved into a2 and d parts that remain associated via disulfide bridges. The a2 part of the protein (950 amino acids) is entirely extracellular, while the d part has a small extracellular part that is attached to a2 and a transmembrane domain with a very short cytoplasmic tail that tethers the protein to the membrane (Davies et al., 2007) .
Much research on a2d-1 has focused on its role in the regulation of calcium channel function and trafficking. However, the presence of a large extracellular region containing a well-known protein-protein interaction fold, the Von Willebrand Factor A (VWF-A) domain, suggests that this protein could serve as a receptor for extracellular ligands. A recent study on skeletal muscle cells, which express high levels of a2d-1, described such a role for a2d-1 in myoblast attachment and extracellular signaling that is independent of calcium channel function (Garcia et al., 2007) .
a2d-1 is the high-affinity receptor for two commonly prescribed antiepileptic, antineuropathic pain medications, gabapentin (GBP, Neurontin) and pregabalin (Lyrica) (Gee et al., 1996) . GBP and pregabalin were initially designed as hydrophobic gamma amino butyric acid (GABA) analogs that could cross the blood-brain barrier. Further studies have shown that even though they posses anticonvulsant properties, they do not bind to GABA receptors or transporters. A recent study using a knockin mouse that expresses a mutant a2d-1 that cannot bind GBP or pregabalin has shown that a2d-1 is the in vivo target for these drugs and that these drugs mediate their therapeutic action through binding to a2d-1 (Field et al., 2006) . GBP and pregabalin do not affect the single-channel kinetics of calcium channels and have only modest effects on neurotransmission (Dooley et al., 2007) . Thus, the cellular mechanisms underlying the mode of action of these drugs are unclear.
In this study, we show that EGF-like domains of TSP directly bind to a2d-1 and mediate its synapse-inducing activity via this receptor. These findings identify a2d-1 as a neuronal TSP receptor that is required for CNS synapse formation. This function of a2d-1 is likely to be independent of calcium channel function. We also show that GBP is a potent inhibitor of TSP/ astrocyte-induced excitatory synapse formation in vitro and in vivo. This function of GBP may be a central part of its mechanism of action.
RESULTS

All TSP Isoforms Induce Synapse Formation
There are five TSP isoforms in mammals, which fall into two groups according to their domain structure and oligomerization states ( Figure 1A ). Trimeric subgroup A TSPs, TSP1 and 2, are synaptogenic (Christopherson et al., 2005) . To determine whether pentameric subgroup B TSPs are also synaptogenic, we cultured RGCs in the presence of astrocytes or with TSP 1, 3, 4, or 5. All subgroup B TSPs increased synapse number significantly to similar levels as TSP1 or astrocytes ( Figures 1B-1D ). These results suggest that the synaptogenic domain of TSP is located in the conserved C-terminal portion of TSP, which is common to all isoforms spanning the EGF-like repeats, the calcium-binding repeats, and C-terminal L-type lectin-like globular domain.
The Synaptogenic Activity of TSP Maps to Its EGF-like Repeats TSPs interact with a number of known cell-surface receptors through specific domains (Adams and Lawler, 2004) . To identify the synaptogenic domain of TSP, we treated RGCs with a panel of recombinant truncation constructs of TSP1 and 2. The TSP fragments that contained the EGF-like repeats mimicked the ability of full-length TSP to induce synapses (Figures 2B and 2C) . A fragment containing the third EGF-like repeat together with the C-terminal region of TSP2 also significantly increased synapse number; however, the third EGF like domain alone did not induce a significant increase in synapse number ( Figure 2C ).
We confirmed the importance of the EGF-like repeats in synapse formation by functionally blocking synaptogenic effect of TSP on cultured RGCs, using monoclonal antibodies directed against different epitopes of TSP ( Figure 2D ). Monoclonal antibodies against the second (HB8432 and C6.7) (Annis et al., 2007) or third EGF-like repeats (A4.1) (Annis et al., 2006) blocked the synaptogenic effect of TSP, whereas an antibody against the N-terminal domain (mAb200-1) did not ( Figure 2E ).
To aid us in our efforts to identify the neuronal TSP receptor involved in synapse formation, we expressed and purified a myc and 6-Histidine tagged TSP2 fragment containing all three EGF-like repeats (Figures S1A and S1B available online). This TSP2 fragment (designated SD2 for synaptogenic domain 2) was strongly synaptogenic (Figures S1C and S1D ). Collectively, these data suggest that TSP-induced synapse formation is mediated by an interaction involving EGF-like repeats of TSP.
a2d-1 Interacts with the Synaptogenic Domain of TSP The EGF-like domains of TSP4 have been shown to bind to the VWF-A domain of integrin aM (Pluskota et al., 2005) . Thus, we investigated whether integrin aM or other VWF-A domain containing integrins in RGCs were involved in TSP-induced synapse formation. None of the integrins that contained the VWF-A domain and were expressed by RGCs were crucial for the synaptogenic activity of TSP (data not shown).
Another class of cell-surface proteins that contains VWF-A domains is the alpha2 delta (a2d) family. Among the a2d proteins cloned to date (Klugbauer et al., 2003) , RGCs express high levels of a2d-1 ( Figure S2A ). We investigated whether a2d-1 is localized to synapses using array tomography (Micheva and Smith, 2007) . Ultra-thin sections from rat cortex or mouse LGN were immunolabeled with antibodies against a2d-1 and the pre-and postsynaptic markers synapsin and MAGUK. a2d-1 gave a punctate staining pattern. Some a2d-1 puncta localized to synapses identified as juxtapositioned pre-and postsynaptic puncta, while some colocalized exclusively with pre-or postsynaptic puncta ( Figures 3A and S2B) .
To determine whether a2d-1 interacts with TSPs, we immunoprecipitated TSP1, 2, and 4 from P5 rat cerebral cortex lysate. a2d-1 was detected in immunoprecipitation fractions performed with each of the three TSP antibodies ( Figure 3B ), suggesting that a2d-1 and TSPs interact in vivo.
To test whether there is a direct and specific binding interaction between the synaptogenic domain of TSP and a2d-1, we coexpressed a FLAG-tagged a2d-1 alone ( Figure 3C Beads conjugated to an anti FLAG-tag antibody were used to immunoprecipitate a2d-1-FLAG. SD2 coimmunoprecipitated with a2d-1-FLAG, but the Control-myc-his protein did not ( Figure 3C , lanes 8 and 9, respectively), suggesting that a2d-1 specifically interacts with the synaptogenic EGFlike domains of TSP.
We hypothesized that the EGF-like domains of TSP interact with the VWF-A domain of a2d-1, which resides in the a2 region of the protein.
So that this could be tested, three a2d-1 constructs, the full-length a2d-1, a2, or VWF-A domain, each with a C-terminal Protein C (PC) tag for purification ( Figure 3D ), were coexpressed with SD2. When we performed PC tag affinity purifications, we could detect SD2 in all three purified fractions ( Figure 3E , lanes 7, 8, and 9). SD2 did not copurify with an unrelated membrane protein that also contained the same PC tag ( Figure 3E , lane 6). These data show that TSP and a2d-1 interact through the synaptogenic EGF-like domains of TSP and the VWF-A domain of a2d-1.
a2d-1 Is the Neuronal TSP Receptor Involved in Synapse Formation
To determine whether a2d-1 plays a role in TSP-induced synapse formation in vitro, we overexpressed a2d-1 in RGCs and tested whether SD2-induced synapse formation was affected. RGCs that overexpressed a2d-1 (identified with GFP coexpression) received twice as many synapses in response to SD2 as did RGCs transfected with empty vector (Figure 4A ), indicating that a2d-1 overexpression enhances TSP-induced synapse formation. a2d-1 overexpression was not sufficient to induce synapse formation in the absence of SD2, suggesting that SD2 is required for the enhancement of synapse formation by a2d-1.
To determine which region of the a2d-1 protein was responsible for its enhancement of SD2-induced synapse formation, we utilized two a2d-1 constructs (schemed in Figure 4A ). Overexpression of a ''a2d-1Adh'' construct that contains the entire extracellular region of a2d-1 followed by the transmembrane domain from an unrelated type 1 membrane protein adhalin (Gurnett et al., 1996) mimicked the effect of full-length a2d-1 in enhancing SD2-induced synapse formation ( Figure 4A ), suggesting that the critical region of a2d-1 maps to the extracellular part of the protein. We next overexpressed a ''d-1 only'' construct (lacking the a2 region), which inhibited SD2-induced synapse formation ( Figure 4A ), indicating that the VWF-A-containing a2 region is necessary for enhancing synaptogenesis and that regions within d-1 may be involved in regulating downstream interactions that are critical for TSP-induced synapse formation.
Since the VWF-A domain of a2d-1 binds TSP, we investigated whether antibodies against the VWF-A domain of a2d-1 would interfere with TSP-induced synapse formation. Two monoclonal antibodies directed against the VWF-A domain of a2d-1, 5A5 and 3B4, recognized a2d-1 in western blots and stained the surface of HEK293 cells overexpressing a2d-1 ( Figures S3A and S3B ). When RGCs were cultured with these antibodies in the presence or absence of TSP and synapse number analyzed, both 5A5 and 3B4 induced synapse formation similar to TSP. A control antibody (OX7) against another RGC surface receptor (Thy1) did not affect synapse formation. The synaptogenic effect of 5A5 or 3B4 was not additive with that of TSP ( Figure 4B ). These data show that antibody binding to the VWF-A domain can mimic TSPs synaptogenic function and suggest that the interaction of TSP with the VWF-A domain of a2d-1 is important for the initiation of synapse formation. Such ligand-mimicking antibodies were also described for VWF-A domain-containing integrins (Wilkins et al., 1996) . To determine whether a2d-1 is required for TSP-induced synapse formation, we used a small interfering RNA (siRNA) knockdown approach. An siRNA pool specific for rat a2d-1 significantly reduced the expression of rat a2d-1 in transfected HEK293 cells ( Figure 4C ). Knockdown of a2d-1 in RGCs with this siRNA pool inhibited astrocyte or TSP-induced synapse formation in vitro ( Figures 4D and 4E ), whereas the nontargeting control siRNA pool (siControl) did not affect synapse formation (Figures 4C and 4D) .
To show that the reduction in synapse formation by the a2d-1 siRNAs was due to the specific knockdown of a2d-1, we tested whether the siRNA inhibition could be rescued by coexpressing an siRNA resistant a2d-1 construct. One of the siRNAs against rat a2d-1, sia2d-1 Duplex 9, blocked overexpression of rat a2d-1 but not human a2d-1 in HEK293 cells ( Figure S4 ). When we cotransfected RGCs with sia2d-1(9) and the human a2d-1 construct, we rescued SD2 or astrocyte-induced synapse formation ( Figure 4F (A) Array tomography analysis of synaptic localization of a2d-1 in cerebral cortex. RGCs were immunostained for synapsin I (blue) and MAGUK (green). a2d-1 puncta (red) associate both with synapses (white circles) and with isolated presynaptic (diamonds) or postsynaptic (squares) puncta. The scale bar represents 2 mm. (B) Western-blot analysis of a2d-1 on the immunoprecipitation (IP) fractions performed with antibodies specific to TSP1, 2, or 4 as well as calcium channel a1C (Cav1.2), or Agrin (positive and negative controls for IP, respectively). (C) Western blot analysis of a2d-1 interaction with the synaptogenic domain of TSP2 (SD2). Left, HEK293 cell lysates from nontransfected (1), a2d-1-FLAG alone (2), SD2 alone (3), a2d-1-FLAG and SD2 (4), and a1d-1FLAG and Control-myc-His construct (5) transfected cells. SD2 and Control-his-myc protein are marked with red d. Anti-his antibody cross-reacts with several histidine rich proteins in HEK293 cell lysates (marked with a blue *). Anti-a2d-1 antibody also weakly recognizes the human a2d-1 expressed endogeneously in HEK293 cells at low levels (blue A) Right, anti-FLAG IP fractions from a2d-1-FLAG alone (6), SD2 alone (7), a2d-1-FLAG and SD2 (8), and a2d-1FLAG and Control-myc-His construct (9) transfections. (D) Domain structure of a2d-1 protein and scheme of a2d-1 protein C (PC) tagged constructs. SP, signal peptide; vWA_N and VGCC_a2, putative domains of unknown structure. Yellow boxes indicate putative helical regions where no domain has yet been predicted. The red box shows the transmembrane (TM) region. Orange hexagons indicate predicted N-glycosylation sites, and purple bars indicate positions of cysteines. (E) SD2 interacts with the VWF-A domain of a2d-1. Lane 1 is nontransfected HEK293 cell lysate. SD2 was coexpressed with PC tagged full-length a2d-1, a2 only, or VWF-A only constructs (lanes 3, 4, and 5) as well as CXCR4. SD2 coimmunopurified with the a2 only (8) and VWF-A only (9) constructs of a2d-1 as well as the full-length protein (7) with anti-PC beads, (red arrows). SD2 did not copurify with CXCR4 (6).
blocks synaptogenesis via specific inhibition of rat a2d-1 messenger RNA (mRNA). Taken together, these results demonstrate that a2d-1 is necessary for TSP and astrocyte-induced and necessity for a2d-1 in astrocyte/TSP-induced synapse formation.
a2d-1-Mediated Synapse Formation Does Not Depend on Calcium Channel Surface Level or Function a2d-1 is known to enhance calcium channel function and trafficking (Arikkath and Campbell, 2003) . We therefore investigated whether the activity of a2d-1 in synapse formation is linked to its role in increasing calcium currents or calcium channel levels. Gene expression analysis of RGCs show that these cells express predominantly postsynaptic L-type and presynaptic N-and P/Qtype voltage gated calcium channels (VGCCs). To directly test whether VGCC function was required for astrocyte-induced synapse formation, we added L-type calcium channel blockers to RGCs to block L-type channel function. These drugs had no effect on SD2-induced synapse formation ( Figure S5A) . Similarly presynaptic N-and P/Q-type channel blockers did not block 
TSP-induced synapse formation (data not shown).
We next investigated whether increase of postsynaptic L-type calcium channel expression in RGCs would enhance synapse formation. Overexpression of L-type a1C and b subunits in RGCs had no effect on astrocyte-induced synapse formation ( Figure S5B ). Finally, we tested whether TSP treatment would lead to an increase in cytoplasmic calcium levels in RGCs. Neither acute nor longterm TSP treatment led to a noticeable rise in spontaneous calcium oscillations in RGCs ( Figure S6 ). Taken together, these results show that the role of a2d-1 in synapse formation cannot be directly linked to calcium channel expression levels or function.
Overexpression of a2d-1 in Neurons Enhances Synapse Formation In Vivo
To determine whether a2d-1 plays a role in synapse formation in vivo, we examined synapse number and synaptic activity in transgenic mice that selectively overexpress a2d-1 in CNS neurons, under the control of the Thy1 promoter (Li et al., 2006) . Sagittal brain sections from 21-day-old (P21) transgenic (TG) and wild-type (WT) littermate mice were coimmunostained for PSD95 and either the presynaptic vesicular glutamate transporter 1 or 2 (VGlut1 and VGlut2). We quantified the number of colocalized pre-and postsynaptic puncta to determine the synaptic density in the cortices of these mice. The TG mice had significantly higher numbers of VGlut2-positive excitatory synapses in the cortex than did the littermate WT controls (1.8-fold, Figures 5A and 5B); however, there was no difference in the number of VGlut1-positive synapses between WT and TG mice ( Figures S7A and S7B) . The observation that a2d-1 overexpression increases VGlut2-positive synapses provides evidence that excitatory synapse formation is enhanced in the TGs.
In the adult cortex thalamic neurons projecting onto layer IV neurons form VGlut2-positive synapses, while synapses made between cortical neurons contain VGlut1 (Fremeau et al., 2004) . We confirmed that the increase in VGlut2-positive synapse number was not due to an increase in the number of neurons in the cortex or thalamus, as the number of cells and neurons in WT and TG brains were identical in these brain regions ( Figures S8A and S8B) .
Excitatory synapses in the cortex are initially formed as VGlut2 positive, and there is an isoform switch to VGlut1 that happens around the second week of postnatal development (Miyazaki et al., 2003) . During this period, some synapses can transiently be both VGlut1 and 2 positive (Nakamura et al., 2005) . We determined that the increase in VGlut2-positive synapses was not due to a prolonged colocalization of VGlut1 and 2 at the same synapse, since these proteins seldom colocalized at P21, and there were no differences in the frequency of colocalization of these proteins between genotypes ( Figures S9A and S9B ). Taken together, these results show that the increase in VGlut2-positive synapses associated with a2d-1 overexpression is due to neither an increase in the number of cortical or thalamic neurons nor a delay in the isoform switch from VGlut2 to 1 in the cortex.
In addition to analyzing synapse number by immunohistochemistry, we performed whole-cell patch-clamp recordings in layer IV cortical pyramidal neurons and assayed the number of active synapses by analyzing the frequency and amplitude of miniature excitatory postsynaptic currents (mEPSCs). Recorded cells were dye filled, and their identity was verified (Figures S10A and S10B). We targeted layer IV pyramidal neurons both because these cells receive VGlut2-positive synapses and because array tomography revealed an increase in a2d-1 immunostaining in TG animals in this layer ( Figure S10C ). There was a highly significant increase in the frequency of mEPSCs in a2d-1 TG mice compared with WT mice (1.63-fold), with no effect on the amplitude of mEPSCs ( Figures 5C-5E ). The increase in the frequency of mEPSCs in TG mice is very consistent with the increased excitatory synapse number found by the immunohistochemical analysis described above. Taken together, these data show that a2d-1 plays a role in promoting excitatory synapse formation in the brain.
Gabapentin, the High-Affinity Ligand for a2d-1, Strongly Inhibits TSP-Induced Synapse Formation In order to determine whether GBP, the high-affinity ligand for a2d-1 affects TSP or astrocyte-induced synapse formation, we cultured RGCs with TSP, SD2, or ACM in the presence or absence of GBP (32 mM). GBP strongly inhibited TSP, SD2, or astrocyte-induced synapse formation ( Figures 6A-6C and S1C). To determine whether GBP could dissolve already established synapses, we cultured RGCs with SD2 for 5 days to allow synapses to form and then added GBP for an additional day. GBP had no effect on synapse number when added after the synapses were formed ( Figure 6C ). Thus, GBP blocks new synapse formation induced by TSP and astrocytes but does not dissolve established synapses. Interestingly, GABA, an inhibitory neurotransmitter that binds to a2d-1 with much lower affinity (IC 50 = 650 mM) (Suman-Chauhan et al., 1993) , also blocked SD2-induced synapse formation when used at high concentrations ( Figure S11 ).
To determine whether GBP blocks TSP-induced synapse formation by inhibiting the a2d-1-TSP interaction, we cocultured two populations of HEK293 cells, one expressing a2d-1FLAG and the other expressing SD2, in the presence or absence of GBP. Immunoprecipitation with anti-FLAG antibodies revealed that the SD2-a2d-1 interaction was diminished in the presence of GBP (Figure 6D ), suggesting that GBP blocks TSP-induced synapse formation by interfering with the interaction between a2d-1 and TSP.
To test whether GBP similarly blocks synapse formation in vivo, we injected neonatal mice with either GBP or saline for the first postnatal week, which coincides with the initiation of synapse formation in the brain. At this age, glutamatergic synapses in the cortex are predominantly VGlut2 positive (Miyazaki et al., 2003) . Therefore, we coimmunostained sagital brain sections from P7 saline-or GBP-injected mice with antibodies against VGlut2 and PSD95 and quantified the number of colocalized pre-and postsynaptic puncta in the cortex of these mice. There were significantly fewer excitatory synapses in the cerebral cortex of the GBP-injected mice relative to control mice ( Figure 6E ). This difference was mainly due to a severe decrease in synapse number in half of the GBP-injected animals. In the mice that responded strongly to GBP, the VGlut2/PSD95 synaptic densities went down profoundly, to less than 10% of the saline-injected values, although the number of neurons did not change. GBP injection affected both VGlut2 and PSD95 puncta by reducing their number, size, and colocalization ( Figure 6E ), similar to its effect on synaptic puncta in vitro. These findings show that GBP is a powerful inhibitor of new synapse formation both in vitro and in vivo.
Inhibition of TSP-Induced Synapse Formation Interferes with Lesion-Induced Barrel Cortex Plasticity
To determine whether astrocyte-induced synapse formation is involved in remodeling neural circuits during development, we utilized a well-established developmental plasticity paradigm, the ''barrel cortex plasticity'' assay. The nerves that innervate the major whiskers on the snout of the mouse project to the brain as a topographically ordered ''somatotopic'' map (Erzurumlu et al., 2006) . In the primary somatosensory cortex, this map is organized as ''barrels'' ( Figure 7A ) that exhibit structural changes in response to peripheral whisker manipulations.
To test whether TSP-induced synapse formation is involved in mechanisms of experience-dependent plasticity, we injected two groups of neonatal mice either with GBP or saline daily starting at P0 until P7. On P1, five whiskers from the C row on one side of each mouse were lesioned. The mice were sacrificed at P7, and barrel cortex organization in both the unlesioned ''control'' and the lesioned hemisphere was analyzed. Both saline-and GBP-injected mice had typical barrel organization formed on the control side ( Figure 7B , top two left panels). On the lesioned side, although all saline-injected mice displayed a normal barrel cortex plasticity pattern, 50% of the GBPinjected mice displayed an atypical plasticity response ( Figure 7B, right panels) , where the A and B rows as well as the C row lost form and fused, even though the whisker follicles for these rows were undisturbed in all mice ( Figures 7B, 7C , and S12).
To more directly test the role of TSPs, we examined barrel cortex plasticity in TSP1/2 double-null (KO) mice. A third of the TSP1/2 KO mice we analyzed showed a very similar, aberrant barrel cortex plasticity phenotype ( Figure 7B, bottom right) , a pattern that we never observed in any of the WT mice. These findings suggest that astrocyte-secreted TSPs are required for rewiring of the barrels post injury and that the main effect of GBP in barrel cortex plasticity is mediated by its inhibition of TSP-induced synapse formation. Red arrows point to SD2 protein coimmunoprecipitated with a2d-1FLAG. Anti-a2d-1 antibody also recognizes weakly expressed endogenous human a2d-1 expressed by HEK293 cells (lanes 2 and 5, top blots).
(E) Quantification of colocalization of VGlut2 and PSD95 in brain sections from saline-and GBP-injected P7 mice. Error bars show the mean ± SEM, *p < 0.05. (F) Immunolabeling of saline-and GBP-injected P7 cortices for VGlut2 (green) and PSD95 (red). Half of GBP-injected mice had a very strong reduction in the number, size, and colocalization of synaptic puncta (white arrows, inset i versus ii). Scale bars represent 20 mm.
DISCUSSION
a2d-1 Is a Neuronal Thrombospondin Receptor Responsible for Synaptogenesis
The molecular interactions that regulate initiation of synapse formation are not well characterized. Our finding that a2d-1 is the TSP receptor required for synaptogenesis provides molecular insight into the mechanism of synapse formation and raises the question of how TSP-a2d-1 interaction leads to initiation of synaptogenesis.
Our findings lead us to the following working model: a2d-1 is the extracellular ligand-binding portion of a postsynaptic ''synaptogenic signaling complex'' ( Figure S13 ) that regulates formation of an initial synaptic adhesion between a dendrite and an axon. TSP binding to the VWF-A domain of a2d-1 causes a structural rearrangement in this molecule, which triggers subsequent conformational shifts in its binding partner(s) and switches this complex to an ''active'' state. a2d-1 activation by TSP then leads to inter-and intracellular signaling events that trigger the recruitment of synaptic adhesion and scaffolding molecules to nascent synaptic sites. VWF-A domains are known protein-protein interaction domains that act as conformational switches and alter a protein's structure upon binding to its ligand (Bork and Rohde, 1991; Whittaker and Hynes, 2002) . The fact that antibodies directed against the VWF-A domain of a2d-1 can mimic the synaptogenic function of TSP also suggests a binding-induced activation of a2d-1 in synapse formation.
It is unlikely that a2d-1 can induce intracellular signaling by itself since it has a very short cytoplasmic tail and the extracellular domain of a2d-1 is able to mimic the full-length a2d-1's function in synapse formation. a2d-1 may be linked to intracellular signaling mechanisms via other membrane proteins. A calcium channel a1 subunit can be a part of this complex. a1, after being recruited by a2d-1 to dendrite-axon contact sites, could undergo conformational changes induced by TSP-a2d-1 interaction and potentially serve as a platform for the nucleation of synaptic proteins at the new synaptic site ( Figure S13 ).
a2d-1 has previously been shown to enhance calcium currents and surface trafficking of calcium channel a1 subunits (Arikkath and Campbell, 2003) . Is a2d-1's role in synapse formation linked to this function? We have several observations that suggest otherwise. First, overexpression of a2d-1 in the absence of TSP enhances calcium channel surface expression (Gurnett et al., 1996) but does not lead to an increase in synapse number. Second, the a2d-1Adh protein can mimic the effect of full-length a2d-1 in enhancing synapse formation, but it does not induce an increase in calcium currents like the full-length protein (Gurnett et al., 1996) . Third, neither the overexpression nor the pharmacological blocking of calcium channels interfered with TSP-induced synapse formation. Similarly, acute or long-term TSP treatment did not increase cytoplasmic calcium levels in RGCs; thus, it is unlikely that TSP triggers activation of a homeostatic mechanism that can activate synapse formation. Taken together, our results show that global changes in calcium channel numbers or currents are not involved in TSP-induced synapse formation. However, since the a2d-1Adh construct, which enhances synapse formation, can interact with the a1 subunit, and since d-1 construct, which inhibits synapse formation, can interfere with the a2d-1 and a1 interaction, a physical interaction between a2d-1 and the calcium channel a1 subunits might be important for synapse formation. Future studies exploring whether knocking down expression of a1 subunits affects TSP-induced synapse formation are necessary to verify this possibility.
a2d-1 might also interact with other proteins that are involved in organization of synaptic contacts. Such dual functions have been described for the g subunits of VGCCs also known as stargazins. They were initially isolated as a component of the calcium channel complex but are now known to play primary roles in AMPA receptor regulation (Chen et al., 2000) . Identification of the relevant a2d-1 interacting molecules promises to provide new molecular insight into the process of synapse formation. In addition, there could be other CNS molecules that share TSP's and GBP's abilities to bind to a2d-1 and trigger or inhibit synapse formation.
Our findings have a number of important implications for future studies. First, TSP and a2d-1 are also highly concentrated at the neuromuscular junction; thus, it is likely that these molecules are involved in formation of this synapse (Arber and Caroni, 1995; Arikkath and Campbell, 2003) . Second, other a2d family members might also regulate synapse formation. In fact, disruption of the a2d-4 gene in mice leads to a severe loss of ribbon synapses in the photoreceptor cells (Wycisk et al., 2006) , and mutations in a2d-3 cause defects in synaptic transmission and a morphological defect in presynaptic organization at the Drosophila neuromuscular junction (Dickman et al., 2008; Kurshan et al., 2009 ). These observations suggest that the function of a2d subunits in promoting synaptogenesis may be evolutionarily conserved and can be exerted presynaptically as well as postsynaptically.
Gabapentin Is a Powerful Blocker of Synapse Formation
Our findings suggest that GBP blocks TSP-induced synapse formation by interfering with TSP-a2d-1 interaction. GBP binding to a2d-1 involves a region just upstream of the VWF-A domain in a2 (Wang et al., 1999) . Therefore, it is unlikely that TSP and GBP compete for the same binding site. It is known for integrins that conformational changes in VWF-A domains can be constrained by interactions made by regions flanking this domain (Bork and Rohde, 1991; Whittaker and Hynes, 2002) . We propose that GBP binding to a2d-1 restricts the conformation of the VWF-A domain and keeps a2d-1 in its ''inactive conformation.'' This perturbs the TSP-a2d-1 interaction and inhibits activation of the synaptogenic signaling complex ( Figure S13) .
GABA, leucine, and isoleucine can also bind to a2d-1, albeit at lower affinity than GBP (Dooley et al., 2007) , and thus they can be physiological ligands for a2d-1 and regulate excitatory synapse formation. In agreement with this, we found that high concentrations of GABA inhibited synapse formation in culture. Such high concentrations of GABA are present in the CNS right next to a GABAergic axon. Dendritic filopodia in the developing brain actively seek for synaptic partners and establish exclusively glutamatergic contacts. Interestingly, dendritic filopodia that contact a GABAergic axon never stabilize the contact and retract (Lohmann and Bonhoeffer, 2008; Wierenga et al., 2008) . In future studies, it will be interesting to explore whether a2d-1 functions as a physiologically relevant GABA receptor that enables initial selectivity for the formation of excitatory synapses by dendritic filopodia.
a2d-1-TSP Interaction Regulates Synapse Formation during Development and after Injury
The ability of GBP to strongly decrease synapse formation in wild-type mouse brains points to a critical role for TSP-a2d-1 interaction and astrocytes in driving synaptogenesis in vivo. In addition, the correct execution of barrel cortex plasticity depends on TSP-induced synapse formation. Since the unlesioned barrel cortices are formed normally both in GBP injected and TSP1/2 KO mice, TSPs might specifically play a role in synaptic remodeling plasticity upon injury in this system. These findings add to the growing data that astrocytes not only actively contribute to normal synaptogenesis but also mediate synaptic remodeling events after injury.
It is interesting that the effect of GBP in vivo is an ''all or none'' effect rather than a fractional decrease in synapse number, and only 50% of the mice responded strongly to GBP injections. It is possible that a critical threshold concentration of GBP in the cerebrospinal fluid is required to be effective in blocking synapse formation, which is only achieved in half of the mice. Gender could be critical in GBP responsiveness by affecting in GBP delivery to neural tissues and can explain the 50% penetrance we have observed. In fact, a recent study demonstrated that intraperitoneal GBP injections were not as effective at blocking seizures in female mice as in males (Traa et al., 2008) .
Since GBP strongly blocks TSP-induced synapse formation within its therapeutic concentration, it is possible that inhibition of excitatory synapse formation is an important mode of its therapeutic action in epilepsy and pain. Reactive astrocytosis is prominent both in epileptic lesions and in the spinal cord after peripheral nerve injury that leads to neuropathic pain (Liu et al., 2000; Ridet et al., 1997) . Reactive astrocytes express high levels of TSP1 and 2 (Lin et al., 2003) . Similarly, upon injury in the spinal nerve, both a2d-1 and TSP4 genes are upregulated in the spinal cord (Valder et al., 2003; Wang et al., 2002) . Increased a2d-1 levels were shown to lead to enhanced excitatory synaptic transmission and elevated neuropathic pain states (Li et al., 2004 (Li et al., , 2006 . Similarly, there is increased excitation in the epileptic brain (Prince, 1999) . All these observations point to the possibility that aberrant excitatory synaptogenesis may contribute to the pathophysiology of neuropathic pain and epilepsy. Thus GBP may act by limiting these excess synapses from forming, a possibility which can now be directly tested in animal models of these diseases. In conclusion, by identifying a2d-1 as a receptor for TSP mediated glial-induced synapse formation, we have gained molecular understanding not only of astrocytes' role in synapse formation in health and disease, but also of the process of synapse formation itself.
EXPERIMENTAL PROCEDURES
Purification and Culture of RGCs and Astrocytes RGCs were purified with greater than 99.5% purity from P5 Sprague-Dawley rats (Charles Rivers) and cultured in serum-free medium as previously described (Christopherson et al., 2005; Meyer-Franke et al., 1995; Ullian et al., 2001) . Cortical astrocyte inserts and ACM were prepared as described in (Christopherson et al., 2005) . RCGs were cultured for 3-4 days to allow robust process outgrowth and then cultured with astrocyte inserts, ACM, or TSPs for an additional 6 days.
Mice TSP1/2 double-null mice on an FVB background were used (n = 12). WT FVB mice were purchased from Charles River Laboratories. Brains from P21, a2d-1-overexpressing, TG mice and their littermate WT controls (n = 8) were provided by Li and colleagues and are described in Li et al. (2006) .
Quantification of Synapse Numbers
For synapse quantification of RGCs, we followed a previously developed immunohistochemistry (IHC)-based method described and validated in Christopherson et al. (2005) and Ullian et al. (2001) . For quantification of excitatory synapse number in mouse brain, three sagital brain sections per animal were stained with pre-and postsynaptic markers, and 5 mm confocal scans were performed (optical section width 0.38 mm, 14 optical sections each) at the cortex. The parameters for scanning were always set up for WT (or salineinjected) brain sections, and the same imaging parameters were used for TG (or GBP-injected) animals. Merged single optical section images at 1 mm intervals were analyzed with the ImageJ puncta analyzer option to count for number of colocalized pre-and postsynaptic puncta (five optical sections/ section, 15 images/brain). Average synaptic density per imaged area was calculated for each condition. Details on IHC conditions, image acquisition, and quantification can be found in Supplemental Data.
Electrophysiological Recordings
Experiments were carried out on littermate WT and a2d-1 transgenic mice aged P21-P25, and recordings and analysis were both carried out blind to genotype. Whole-cell voltage-clamp recordings of layer IV pyramidal neurons in the visual cortex were carried out at room temperature in flowing isotonic saline containing 1 mM tetrodotoxin (TTX) and 40 mM bicuculline to isolate mEPSCs. mEPSCs were recorded for one minute and analyzed with Minianalysis software from Synaptosoft.
Saline and Gabapentin Injections
Mice were given daily intraperitoneal injections of either a single dose of 400 mg/kg of GBP (Sigma-Aldrich) or a matching volume of saline solution (PBS). Pups were weighed just before injections to determine the dose administered and to follow weight gain and general health, which showed no differences between GBP-and saline-injected mice.
Whisker Lesions and Barrel Cortex Immunohistochemistry
Neonatal mice were held on their left side under a dissecting scope and received two parallel incisions with a surgical blade flanking the C row of whiskers to be removed. The skin between the incisions was pulled back with forceps. Follicles were individually removed with forceps at the opening. The lesion site was then cauterized with silver nitrate using flexible caustic applicators (Tech-Med). Mice were allowed to recover in their home cage. P7 mice were sacrificed, and brains were harvested. Samples were blinded during rest of the analysis of the barrel cortex plasticity. Tangential cortical sections were stained with anti-serotonin (5-HT) transporter rabbit polyclonal antibody (Calbiochem, 1:400) Barrels were imaged with a Nikon Eclipse E800 fluorescent microscope, and images were digitally acquired with an SPOT camera (Diagnostic Instruments). The complete maps of the barrel cortex were reassembled from 5-HTT-stained images of serial sections by reconstruction in Photoshop (Adobe Systems). Details on the immunohistochemistry conditions, image acquisition, and data analysis can be found in Supplemental Data.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and 13 figures and can be found with this article online at http://www.cell.com/ supplemental/S0092-8674(09)01185-4.
